Latest news

China grabs 32% of global biotech deal value in 2025 surge

China grabs 32% of global biotech deal value in 2025 surge

Joachim Eeckhout
Daily Snap - 15. July 2025

Daily Snap - 15. July 2025

Joachim Eeckhout
Biotech job cuts continue as three more companies slash workforces

Biotech job cuts continue as three more companies slash workforces

Joachim Eeckhout
FDA rejects Capricor’s Duchenne cell therapy, citing lack of proven benefit

FDA rejects Capricor’s Duchenne cell therapy, citing lack of proven benefit

Joachim Eeckhout
Daily Snap - 14. July 2025

Daily Snap - 14. July 2025

Joachim Eeckhout
Renasant Bio launches with $54.5M to tackle rare kidney disease

Renasant Bio launches with $54.5M to tackle rare kidney disease

Joachim Eeckhout
AbbVie pays $700 million upfront for a trispecific antibody from Ichnos Glenmark Innovation

AbbVie pays $700 million upfront for a trispecific antibody from Ichnos Glenmark Innovation

Joachim Eeckhout
Actithera lands $75.5M to chase next-gen cancer radiopharma

Actithera lands $75.5M to chase next-gen cancer radiopharma

Joachim Eeckhout
Merck bets $10B on COPD breakthrough with Verona Pharma buyout

Merck bets $10B on COPD breakthrough with Verona Pharma buyout

Joachim Eeckhout
Concentra snaps up troubled Cargo Therapeutics in latest biotech acquisition

Concentra snaps up troubled Cargo Therapeutics in latest biotech acquisition

Joachim Eeckhout
ProKidney’s cell therapy shows promise in chronic kidney disease trial

ProKidney’s cell therapy shows promise in chronic kidney disease trial

Joachim Eeckhout
Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Joachim Eeckhout
FirstBack
14151617181920
Next Last